Laser postionization secondary neutral mass spectrometry in tissue: a powerful tool for elemental and molecular imaging in the development of targeted drugs

Wittig, Andrea; Arlinghaus, Heinrich F.; Kriegeskotte, C.; Moss, R.; Appelman, K.; Schmid, Kurt Werner; Sauerwein, W.

doi:10.1158/1535-7163.mct-08-0191

Cited by 29 publications

(24 citation statements)

References 40 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This factor is the primary limitation on detecting and imaging low-abundance molecules. Post-ionization of the neutrals is possible, although further fragmentation of molecules is a primary challenge for this approach (49,115). A great deal of instrumentation development has been devoted to focusing and rastering the primary ion beam and optimizing secondary ion collection optics, and although beyond the scope of this review, this greatly affects the sensitivity of the measurement (13,16).…”

Section: Tof-simsmentioning

confidence: 99%

Advances in Imaging Secondary Ion Mass Spectrometry for Biological Samples

Boxer

Kraft

Weber

2009

Annu. Rev. Biophys.

285

277

View full text Add to dashboard Cite

Imaging mass spectrometry combines the power of mass spectrometry to identify complex molecules based on mass with sample imaging. Recent advances in secondary ion mass spectrometry have improved sensitivity and spatial resolution, so that these methods have the potential to bridge between high-resolution structures obtained by X-ray crystallography and cyro-electron microscopy and ultrastructure visualized by conventional light microscopy. Following background information on the method and instrumentation, we address the key issue of sample preparation. Because mass spectrometry is performed in high vacuum, it is essential to preserve the lateral organization of the sample while removing bulk water, and this has been a major barrier for applications to biological systems. Recent applications of imaging mass spectrometry to cell biology, microbial communities, and biosynthetic pathways are summarized briefly, and studies of biological membrane organization are described in greater depth.

show abstract

Section: Tof-simsmentioning

confidence: 99%

Advances in Imaging Secondary Ion Mass Spectrometry for Biological Samples

Boxer

Kraft

Weber

2009

Annu. Rev. Biophys.

285

277

View full text Add to dashboard Cite

show abstract

“…The results showed that the distribution of KA-BSH was different from that of BPA or BSH. BPA was reported as widely distributed in the cytoplasm and the cell nuclei with no regions in which the concentration of BPA is especially high [ 35 , 36 ]. Indeed, BPA was widely distributed in the cytoplasm and cell nuclei herein ( Figure 2 E–H).…”

Section: Resultsmentioning

confidence: 99%

Synthesis and Evaluation of Dodecaboranethiol Containing Kojic Acid (KA-BSH) as a Novel Agent for Boron Neutron Capture Therapy

Takeuchi

Hattori

Kawabata

et al. 2020

Cells

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is a form of tumor-cell selective particle irradiation using low-energy neutron irradiation of boron-10 (10B) to produce high-linear energy transfer (LET) alpha particles and recoiling 7Li nuclei (10B [n, alpha] 7Li) in tumor cells. Therefore, it is important to achieve the selective delivery of large amounts of 10B to tumor cells, with only small amounts of 10B to normal tissues. To develop practical materials utilizing 10B carriers, we designed and synthesized novel dodecaboranethiol (BSH)-containing kojic acid (KA-BSH). In the present study, we evaluated the effects of this novel 10B carrier on cytotoxicity, 10B concentrations in F98 rat glioma cells, and micro-distribution of KA-BSH in vitro. Furthermore, biodistribution studies were performed in a rat brain tumor model. The tumor boron concentrations showed the highest concentrations at 1 h after the termination of administration. Based on these results, neutron irradiation was evaluated at the Kyoto University Research Reactor Institute (KURRI) with KA-BSH. Median survival times (MSTs) of untreated and irradiated control rats were 29.5 and 30.5 days, respectively, while animals that received KA-BSH, followed by neutron irradiation, had an MST of 36.0 days (p = 0.0027, 0.0053). Based on these findings, further studies are warranted in using KA-BSH as a new B compound for malignant glioma.

show abstract

“…Ex-vivo, the quantification and the distribution of boron in tissues are also possible using elemental imaging. Such modalities might give some additional and valuable information at the cell and the tissue scales, using secondary ion mass spectrometry (SIMS) [63], laser secondary neutral mass spectrometry (laser-SNMS) [64,65], or laser-induced breakdown spectroscopy (LIBS) [62]. LIBS is an all-optical technique working at room temperature and atmosphere, allowing the reconstruction of elemental imaging from the mapping of a sample.…”

Section: Small Moleculesmentioning

confidence: 99%

Theranostics in Boron Neutron Capture Therapy

Sauerwein

Sancey

Hey‐Hawkins

et al. 2021

Life

Self Cite

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) has the potential to specifically destroy tumor cells without damaging the tissues infiltrated by the tumor. BNCT is a binary treatment method based on the combination of two agents that have no effect when applied individually: 10B and thermal neutrons. Exclusively, the combination of both produces an effect, whose extent depends on the amount of 10B in the tumor but also on the organs at risk. It is not yet possible to determine the 10B concentration in a specific tissue using non-invasive methods. At present, it is only possible to measure the 10B concentration in blood and to estimate the boron concentration in tissues based on the assumption that there is a fixed uptake of 10B from the blood into tissues. On this imprecise assumption, BNCT can hardly be developed further. A therapeutic approach, combining the boron carrier for therapeutic purposes with an imaging tool, might allow us to determine the 10B concentration in a specific tissue using a non-invasive method. This review provides an overview of the current clinical protocols and preclinical experiments and results on how innovative drug development for boron delivery systems can also incorporate concurrent imaging. The last section focuses on the importance of proteomics for further optimization of BNCT, a highly precise and personalized therapeutic approach.

show abstract

Laser postionization secondary neutral mass spectrometry in tissue: a powerful tool for elemental and molecular imaging in the development of targeted drugs

Cited by 29 publications

References 40 publications

Advances in Imaging Secondary Ion Mass Spectrometry for Biological Samples

Advances in Imaging Secondary Ion Mass Spectrometry for Biological Samples

Synthesis and Evaluation of Dodecaboranethiol Containing Kojic Acid (KA-BSH) as a Novel Agent for Boron Neutron Capture Therapy

Theranostics in Boron Neutron Capture Therapy

Contact Info

Product

Resources

About